SEC Tracker
Get the app
SKIN · XBRL financial data

SkinHealth Systems financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (SKIN's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers97,41396,821*81,40390,59478,80283,495*69,58078,18770,65582,368*64,91072,113
Cost of revenue109,96651,135*33,04249,65438,15331,149*21,00029,07525,02129,330*20,47122,775
Gross profit(12,553)45,686*48,36140,94040,64952,346*48,58049,11245,63453,038*44,43949,338
Research and development1,8393,046*2,8071,1591,1081,222*9981,2511,6981,681*1,1021,407
General and administrative36,97828,975*28,86131,41033,43631,756*33,56527,45229,25027,682*21,94323,341
Total operating expenses69,54864,046*65,35263,05162,16459,503*60,60351,81251,87652,876*46,24045,766
Operating income (loss)(82,101)(18,360)*(16,991)(22,111)(21,515)(7,157)*(12,023)(2,700)(6,242)162*(1,801)3,572
Interest income6,7506,391*5,3564,1944,8762,218*3,0283,1581,2561,512*1,4851,290
Interest expense3,4453,358*3,0292,4522,4682,463*2,4984,1446,3116,373*6,3466,295
Other income (expense)4,872(137)*16,08717,3196988*6018,146601124*1,04419
Income tax expense (benefit)3,479603*(659)(353)1,948(1,388)*892(993)3863,296*(184)1,208
Net income (loss)(73,818)(9,403)*(679)202(18,291)(10,330)*(10,096)19,712(11,031)(8,104)*(6,630)(2,669)
Earnings per share, basic USD per share(0.56)(0.07)*(0.01)0.00(0.15)(0.08)*(0.08)0.16(0.09)(0.06)*(0.05)(0.02)
Earnings per share, diluted USD per share(0.56)(0.07)*(0.10)(0.10)(0.15)—(0.08)0.03(0.09)(0.05)*(0.05)(0.02)
Weighted average shares, basic thousands of shares132,897128,716*123,120123,719124,058124,404*125,079126,073126,891127,440*127,793129,597
Weighted average shares, diluted thousands of shares132,897128,716*144,477141,928124,058159,523*125,079140,294126,891150,744*131,400129,597

Balance sheet

CSV

Fiscal quarters (SKIN's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents559,444523,025444,634349,544358,892370,063373,031212,000219,397232,673204,358206,074
Accounts receivable66,80954,69747,66641,40936,27927,64323,25825,04622,20621,74118,61517,640
Inventory74,87891,32195,72177,14373,44369,11365,63259,18756,14648,01247,69346,842
Prepaid and other current assets35,89128,87725,59921,12916,0349,4877,1787,7947,4325,3955,39122,693
Total current assets738,011698,252614,824489,626485,047477,124469,373306,107308,367309,517277,695295,241
Right-of-use asset13,34312,12016,38314,94214,59913,59012,47911,53513,61211,57020,29319,397
Goodwill124,679125,818125,365124,822125,455123,499124,260126,273126,497126,621126,246126,349
Total assets973,074929,113844,741711,833699,548685,683673,820507,565503,636499,803473,233486,573
Accounts payable35,88344,76837,31226,68623,08421,94123,14322,97617,29415,63115,88516,051
Accrued liabilities30,49119,84624,39524,04428,09320,00216,74713,64319,31515,38418,72231,605
Total current liabilities125,879115,00893,56875,42673,94868,15262,80459,44161,904186,275155,202168,198
Lease liability, non-current10,1059,31913,68812,70412,09310,8139,6288,47010,5519,23818,75117,975
Total liabilities883,117869,723781,446642,644639,824633,880627,758433,562437,976438,747417,993431,005
Accumulated deficit(469,464)(478,867)(479,546)(479,344)(497,635)(507,965)(518,061)(498,349)(509,380)(517,484)(524,114)(526,783)
Total stockholders' equity89,95759,39063,29569,18959,72451,80346,06274,00365,66061,05655,24055,568
Total liabilities and equity973,074929,113844,741711,833699,548685,683673,820507,565503,636499,803473,233486,573
Common shares outstanding (cover page) thousands of shares131,267123,427123,632124,020124,122125,245125,994126,825127,503127,773129,600130,141

Cash flows

CSV

Fiscal quarters (SKIN's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(73,818)(9,403)*(679)202(18,291)(10,330)*(10,096)19,712(11,031)(8,104)*(6,630)(2,669)
Stock-based compensation8,185*2,258*6,6366,4987,7125,850*3,4765,3082,4553,585*2,0792,895
Net cash from operating activities17,964*(5,170)*(16,854)6,201*10,315*16,472*2,9969,646*9,647*15,196*(5,554)2,671*
Purchases of property and equipment174*28*344334*4*74*4592*27*139*224427*
Net cash from investing activities(4,436)*(2,168)*(1,802)(2,038)*(2,092)*(862)*(1,145)(1,552)*(1,084)*(1,382)*(1,649)(1,205)*
Share repurchases—30,155*———year only———year only——
Net cash from financing activities(2,350)*(31,357)*(58,618)(98,749)*(204)*(770)*(250)(173,361)*(803)*(512)*(20,906)(224)*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
SkinHealth Systems206,07472,1132,671*130.1M— 10-QJun 30, 2026
Sight Sciences79,75323,388(5,663)*55.1M14.1 quarters 10-QJun 30, 2026
Profound Medical38,2712,483(11,338)*36.5M3.4 quarters 10-QJun 30, 2026
Stereotaxis10,4917,670(3,675)*100.2M2.9 quarters 10-QJun 30, 2026
Utah Medical Products87,5288,5291,383*3.2M— 10-QJun 30, 2026
Sanara MedTech15,42128,1372,038*9.2M— 10-QJun 30, 2026
Anika Therapeutics38,41232,610(684)*13.4M56.2 quarters 10-QJun 30, 2026
Heartflow34,36264,082(8,577)*87.0M19.0 quarters 10-QJun 30, 2026
AVITA Medical9,13921,702(3,496)*30.9M3.2 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.